The impact of nanoparticle ligand density on dendritic-cell targeted vaccines

Biomaterials

Volumn 32, Issue 11, 2011, Pages 3094-3105

  Bandyopadhyay, Arunima ^a   Fine, Rebecca L ^b,c   Demento, Stacey ^a   Bockenstedt, Linda K ^b   Fahmy, Tarek M ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WILLIAMS COLLEGE   (United States)

Author keywords

C type lectin; Cytokines; Dendritic cells; Nanoparticles; Vaccines

Indexed keywords

ANTI-INFLAMMATORIES; ANTIGEN DELIVERY SYSTEM; BIODEGRADABLE NANOPARTICLE; C-TYPE LECTINS; CYTOKINE RESPONSE; CYTOKINES; DENDRITIC CELLS; LIGAND DENSITY; NANOPARTICLE SURFACE; SCAVENGER RECEPTOR; SIMILAR PATTERN; T CELLS; T-CELL RESPONSE; TARGETED NANOPARTICLE; VACCINE DELIVERY SYSTEM;

ANTIGENS; CELLS; LIGANDS; VACCINES;

NANOPARTICLES;

AVIDIN; BIOTIN; INTERLEUKIN 10; LECTIN DEC 205 RECEPTOR; LECTIN RECEPTOR; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CROSS LINKING; DENDRITIC CELL; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; INTERLEUKIN-10; LECTINS, C-TYPE; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NANOPARTICLES; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; VACCINES;

MUS;

EID: 79951577063     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.12.054     Document Type: Article

References (55)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 39:245-252.
2. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Microbiol Immunol 2006, 311:17-58.
3. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
4. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008, 118:1427-1436.
5. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
6. Bozzacco L., Trumpfheller C., Siegal F.P., Mehandru S., Markowitz M., Carrington M., et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007, 104:1289-1294.
7. Idoyaga J., Cheong C., Suda N., Suda J., Kim Y., Lee H., et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008, 180:3647-3650.
8. Singh S.K., Stephani J., Schaefer M., Kalay H., García-Vallejo J.J., den Haan J., et al. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 2009, 47:164-174.
9. Trumpfheller C., Finke J.S., López C.B., Moran T.M., Moltedo B., Soares H., et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006, 203:607-617.
10. Gurer C., Strowig T., Brilot F., Pack M., Trumpfheller C., Arrey F., et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112:1231-1239.
11. Bala I., Hariharan S. Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387-422.
12. Walter E., Dreher D., Kok M., Thiele L., Kiama S.G., Gehr P., et al. Hydrophilic poly(dl-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release 2001, 76:149-168.
13. Park J., Fong P.M., Lu J., Russell K.S., Booth C.J., Saltzman W.M., et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 2009, 4:410-418.
14. Demento S.L., Bonafé N., Cui W., Kaech S.M., Caplan M.J., Fikrig E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 2010, 185:2989-2997.
15. Xiang S.D., Cordella S., Ho J., Apostolopoulos V., Plebanski M. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 3:205-218.
16. Kaiser-Schulz G., Heit A., Quintanilla-Martinez L., Hammerschmidt F., Hess S., Jennen L., et al. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J Immunol 2007, 179:2797-2807.
17. Fahmy T.M., Demento S.L., Caplan M.J., Mellman I., Saltzman W.M. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 2008, 3:343-355.
18. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Saltzman W.M., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013-3021.
19. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006, 24:4201-4211.
20. Gupta P.N., Khatri K., Goyal A., Mishra K., Vyas S.P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007, 15:701-713.
21. Feng L., Qi X.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release 2006, 112:35-42.
22. Jaganathan K.S., Singh P., Prabakaran D., Mishra V., Vyas S.P. Development of a single-dose stabilized poly(d, l-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol 2004, 56:1243-1250.
23. Yuba E., Kojima C., Harada A., Tana A., Watarai S., Kono K. pH-sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 2010, 31:943-951.
24. Xu L., Kurtz S.L., Liu J., Braunstein M., McMurray D.N., Hickey A.J. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. J Pharm Res 2007, 24:1834-1843.
25. Gutierro I., Hernández R.M., Igartua M., Gascón A.R., Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002, 21:67-77.
26. Fahmy T.M., Samstein R.M., Harness C.C., Saltzman W.M. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005, 26:5727-5736.
27. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 2008, 16:765-772.
28. Clawson C, Huang CT, Futalan D, Seible M, Saenz R, Larsson M, et al. Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity Nanomedicine 2010 Oct;6(5):651-61.
29. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
30. Moore K.J., Khoury E.J., Medeiros L.A., Terada K., Geula C., Luster A.D., et al. CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 2002, 277:47373-47379.
31. Serghides L., Smith T.G., Patel S.N., Kain K.C. CD36 and malaria: friends or foes?. Trends Parasitol 2003, 10:461-469.
32. Shrimpton R.E., Butler M., Morel A.S., Eren E., Hue S., Ritter M.A. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol 2009, 46:1229-1239.
33. Chung E.Y., Liu J., Homma Y., Zhang Y., Brendolan A., Saggese M., et al. Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 2007, 27:952-964.
34. Sharp F.A., Ruane D., Class B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009, 106:870-875.
35. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178:2979-2986.
36. Heuking S., Adam-Malpel S., Sublet E., Iannitelli A., Stefano A., Borchard G. Stimulation of human macrophages (THP-1) using toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J Drug Target 2009, 17:662-670.
37. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
38. Diwan M., Elamanchili P., Lane H., Gainer A., Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target 2003, 11:495-507.
39. Elamanchili P., Lutsiak C.M., Hamdy S., Diwan M., Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007, 30:378-395.
40. Borges O., Cordeiro-da-Silva A., Tavares J., Santarém N., de Sousa A., Borchard G., et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008, 69:405-416.
41. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
42. Jones K.S. Biomaterials as vaccine adjuvants. Biotechnol Prog 2008, 24:807-814.
43. Tacken P.J., Torensma R., Figdor C.G. Targeting antigens to dendritic cells in vivo. Immunobiology 2006, 21:599-608.
44. Espuelas S., Thumann C., Heurtault B., Schuber F., Frisch B. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug Chem 2008, 19:2385-2393.
45. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000, 151:673-684.
46. Kwon Y.J., James E., Shastri N., Fréchet J.M. In vivo targeting of dendritic cells microparticles. Proc Natl Acad Sci USA 2005, 102:18264-18268.
47. Chieppa M., Bianchi G., Doni A., Del Prete A., Sironi M., Laskarin G., et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003, 171:4552-4560.
48. Puffer E.B., Pontrello J.K., Hollenbeck J.J., Kink J.A., Kiessling L.L. Activating B cell signaling with defined multivalent ligands. ACS Chem Biol 2007, 2:252-262.
49. Gestwicki J.E., Cairo C.W., Strong L.E., Oetjen K.A., Kiessling L.L. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc 2002, 124:14922-14933.
50. Ullrich' A., Schlessingert J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
51. Silverstein R.L., Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009, 2:1-8.
52. Silverstein R.L., Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol 2000, 11:483-491.
53. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002, 277:47373-47379.
54. Tagliani E., Guermonprez P., Sepúlveda J., López-Bravo M., Ardavín C., Amigorena S., et al. Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells. J Immunol 2008, 180:3201-3209.
55. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176:61693-61702.